Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Denali Therapeutics Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Denali Therapeutics secured $200 million in gross proceeds from a royalty funding agreement with Royalty Pharma following FDA accelerated approval of tividenofusp alfa, significantly strengthening the company's financial position to advance its neurodegenerative disease pipeline.
Key Takeaways
Denali closed a $200 million synthetic royalty funding transaction on March 27, 2026, providing substantial capital without traditional debt or equity dilution
FDA granted accelerated approval of tividenofusp alfa on March 24, 2026, validating the company's lead therapeutic candidate and triggering the funding agreement
2 more takeaways
Related Filings (4)
4 more filings from Denali Therapeutics Inc. in the last 90 days